-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Spyre Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2014 to 2023.
- Spyre Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $18K, a 500% increase year-over-year.
- Spyre Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $50K, a 31.6% increase year-over-year.
- Spyre Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$26K, a 80.9% increase from 2022.
- Spyre Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$136K, a 196% decline from 2021.
- Spyre Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $141K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)